Clinical Trial

The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL

Study acronym: SILVERGLO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen in older treatment-naive patients with large B-cell lymphoma.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-09
Trial Details
NCT Number NCT07514169
Lead Sponsor Ruijin Hospital
Conditions Large B-Cell Lymphoma (LBCL)
Enrollment 30 participants
Start Date 2026-03-31
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-08